A randomised double-blind parallel group multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)

A randomised  double-blind  parallel group  multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death  myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease (EUCLID   Examining Use of tiCagreLor In paD)

Brief description of study

This study is designed to test the hypothesis that ticagrelor monotherapy when compared with clopidogrel monotherapy will reduce the incidence of atherothrombotic ischaemic events, as measured by the composite of CV death, MI, and ischaemic stroke in patients with established PAD. Patients will receive either 90 mg ticagrelor orally bd and clopidogrel placebo in the morning, or 75 mg clopidogrel od (morning) and ticagrelor placebo bd. The patients will be followed for an anticipated minimum of 18 months and up to approximately 36 months.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Peripheral Vascular Diseases, Peripheral Arterial Disease
  • Age: Between 1 Years - 99 Years
  • Gender: All
Updated on 27 Sep 2017. Study ID: 817042

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center